**CARES**

**Trial design:** Patients with gout and cardiovascular disease were randomized to febuxostat (n = 3,098) vs. allopurinol (n = 3,092). Follow-up was a median of 32 months.

**Results**
- Cardiovascular death, myocardial infarction, stroke, or urgent revascularization for unstable angina: 10.8% of the febuxostat group vs. 10.4% of the allopurinol group (p = 0.66, p for noninferiority = 0.002)
- All-cause mortality: 7.8% with febuxostat vs. 6.4% with allopurinol (p = 0.04)
- Cardiovascular mortality: 4.3% with febuxostat vs. 3.2% with allopurinol (p = 0.03)

**Conclusions**
- Among patients with gout and cardiovascular disease, febuxostat was noninferior to allopurinol at preventing adverse cardiovascular events
- However, febuxostat was associated with an increase in all-cause and cardiovascular mortality